Neogen's stock fell 7.22% following an FDA warning about their recalled veterinary product HYCOAT, which was linked to fungal contamination and at least 20 horse deaths. The FDA found multiple fungal species in a product marketed as sterile, affecting nearly 100 horses. Neogen's Animal Safety segment, which includes HYCOAT, generated $54.5 million in Q3 fiscal 2026. Legal investigations are underway regarding potential securities violations, and investors who suffered losses are encouraged to submit claims for possible recovery.
Neogen's securities investigation notice provides context for health sector trading. For readers following health stocks, here is Pluang's market snapshot as of Oct 07, 2026 20:05 WIB: Out of 100 priced health-sector US stocks, 46 rose and 50 fell. Notable movers include AMWL at USD 12.71 with a 3.59% increase and 100% sell order activity, DNA at USD 11.99 down 3.38% with 58% buy orders, and NUWE at USD 0.72 up 3.24% with 44% buy orders.
BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
